Kantonsspital St.Gallen

STORM: A randomized phase II Trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases

Paul Martin Putora

abstract To compare metastases-free survival (MFS) between metastasis-directed therapy and metastases-directed therapy with whole pelvis radiotherapy for oligorecurrent nodal prostate cancer.
Target: 178 Patients
project partner Research sites: Belgium and Switzerland
Planned Sites: Norway. Netherlands, Germany, Spain, Italy and australia
type of project clinical studies
status ongoing - follow up
start of project 2019
end of project 2025
study design Multicenter, randomized Phase II
responsible person Dr. Paul Martin Putora